Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Liposomes
Patent
1993-02-12
1994-12-20
Draper, Garnette D.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Liposomes
435697, 436829, 514964, 514 2, A61K 3722
Patent
active
053745485
ABSTRACT:
Novel fusions of a GPI signal domain and a polypeptide heterologous to the GPI signal domain donor polypeptide are provided for industrial use. Therapeutic administration of the GPI-linked product of the fusions enables the targeting of biological activity to cell membrane surfaces.
REFERENCES:
patent: 3993754 (1976-11-01), Rahman
patent: 4480041 (1984-10-01), Myles et al.
patent: 4687661 (1987-08-01), Kikuchi et al.
patent: 5109113 (1992-04-01), Caras et al.
patent: 5223394 (1993-06-01), Wallner
J. R. Murphy et al, PNAS 83:8258 Nov. 1986.
Caras et al., "Analysis of the Signal for Attachment of a Glycophospholipid Membrane Anchor", J. Cell. Biol., 108: 1387-1396 (1989).
Seki et al., "Structural organization of the rat thy-1 gene", Nature, 313: 485-487 (1985).
Seki et al., "Hydrophobic Transmembrane Segment at the Carboxyl Terminus of Thy-1", Science, 227 649-651 (1985).
Schumacher et al., "Primary structure of Torpedo californica acetylcholinesterase deduced from its cDNA sequence", Nature, 319: 407-409 (1986).
Kam et al., "Cloning, sequencing, and chromosomal localization of human term placental alkaline phosphatase cDNA", P.N.A.S., 82, 8715-8719 (1985).
T. Moriuchi et al., "Rat Thy-1 antigen has a hydrophobic segment at the carboxyl terminus", FEBS Lett. 178(1):105-108 (1985).
Cross, G. A. M., "Structure of the variant glycoproteins and surface coat of Trypanosoma brucei", Philos Trans. R. Soc. London, Ser. B 307:3-12 (1984).
Weiss et al., "Isolation and characterization of a cDNA encoding a human liver/bone/kidney-type alkaline", Proc. Natl. Acad. Sci. USA 83:7182-7186 (1986).
Moran & Caras, "Fusion of Sequence Elements from Non-anchored Proteins to Generate a Fully Functional Signal for Glycophosphatidylinositol Membrane Anchor Attachment", J. Cell. Biol., 115(6): 1595-1600 (1991).
Moran et al., "Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo," J. Immunol., 149: 1736-1743 (1992).
Low et al., "Phosphatidylinositol is the membrane-anchoring domain of the Thy-1 glycoprotein", Nature (London), 318: 62-64 (1985).
Cross, G. A. M., "Eukaryotic protein modification and membrane attachment via phosphatidylinositol", Cell, 48: 179-181 (1987).
Davitz et al., "Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC)," J. Exp. Med., 163: 1150-1161 (1985).
Low & Finean, "Specific release of plasma membrane enzyme by a phosphatidylinositol-specific phospholipase C", Biochimica et Biophysica Acta, 508: 565-570 (1978).
Futerman et al., "Physiochemical behaviour and structural characteristics of membrane-bound acetylcholinesterase from Torpedo electric organ", Biochem. J., 226: 369-377 (1985).
Tse et al., "A Glycophospholipid Tail at the Carboxyl Terminus of the Thy-1 Glycoprotein of Neurons and Thymocytes", Science, 230:1003-1008 (1978).
Low, M. G. et al., "Covalently attached phosphatidylinositol as a hydrophobic anchor for membrane proteins", TIBS, 11: 212-215 (1986).
Caras, et al., "Signal for Attachment of a Phospholipid Membrane Anchor in Decay Accelerating Factor" Science 238:1280-1282 (Nov. 1987).
Caras, et al., "Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins", Nature 325:545-549 (Feb. 1987).
Fearon, "Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane", Proc. Natl. Acad. Sci. USA 76(11):5867-5871 (Nov. 1979).
Ferguson et al., "Glycosyl-sn-1,2-dimyristylphosphatidylinositol is Covalently Linked to Trypanosoma brucei Variant Surface Glycoprotein", J. Biol. Chem. 260(27):14547-14555 (1985).
Holers, et al., "Human C3b- and C4b-regulatory proteins: a new multi-gene family" Immunology Today 6(6):188-192 (1985).
Iida et al., "Complement Receptor is an Inhibitor of the Complement Cascade" J. Exp. Med. 153:1138-1150 (May 1981).
Iida et al., "Complement Receptor (CR1) Deficiency in Erythrocytes from Patients with Systemic Lupus Erythematosus" J. Exp. Med. 155:1427-1438 (May 1982).
Low, "Biochemistry of the glycosyl-phosphatidylinositol membrane protein anchors" Biochem. J. 244:1-13 (1987).
Medicus et al., "Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules" Eur. J. Immunol. 13:465-470 (1983).
Medof, et al., "Inhibition of Complement Activation on the Surface of Cells After Incorporation of Decay-Accelerating Factor (DAF) into their Membranes" J. Exp. Med. 160:1558-1578 (Nov. 1984).
Medof, et al., "Decay Accelerating Factor of Complement Is Anchored to Cells by a C-Terminal Glycolipid" Biochemistry 25:6740-6747 (1986).
Medof, et al., "Cloning and characterization of cDNAs encoding the complete sequence of decay-accelerating factor of human complement" Proc. Natl. Acad. Sci. USA 84:2007-2011 (Apr. 1987).
Medof, et al., "Control of the Function of Substrate-Bound C4b-C3b By the Complement Receptor CR1" J. Exp. Med. 159:1669-1685 (Jun. 1984).
Medof, et al., "Unique Role of the Complement Receptor CR1 in the Degradation of C3b Associated with Immune Complexes" J. Exp. Med. 156:1739--1754 (Dec. 1982).
Miyakawa, et al., "Defective Immune-Adherence (C3b) Receptor on Erythrocytes from Patients with Systemic Lupus Erythematosus" The Lancet 493-497 (Sep. 1981).
Nicholson-Weller, et al., "Isolation of a Human Erythrocyte Membrane Glycoprotein with Decay-Accelerating Activity for C3 Convertases of the Complement System" J. of Immunology 129(1):184-189 (Jul. 1982).
Nicholson-Weller, et al., "Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor" PNAS 80:5066-5070 (Aug. 1983).
Pangburn, et al., "Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria" PNAS 80:5430-5434 (Sep. 1983).
Pangburn, et al., "Paroxysmal Nocturnal Hemoglobinuria: Deficiency in Factor H-Like Functions of the Abnormal Erythrocytes" J. Exp. Med. 157:1971-1980 (Jun. 1983).
Ross, et al., "Generation of Three Different Fragments of Bound C3 with Purified Factor I or Serum" J. of Immunology 129:(5):2051-2060 (Nov. 1982).
Taylor, et al., "Decreased Complement Mediated Binding of Antibody/3H-dsDNA Immune Complexes to the Red Blood Cells of Patients with Systemic Lupus Erythematosus, Theumatoid Arthritis, and Mematologic Malignancies" Arthritis and Theumatism, 26 (6):736-744 (Jun. 1983).
Templeton et al., "Construction and Expression of a Recombinant DNA Gene Encoding a Polyomavirus Middle-Size Tumor Antigen with the Carboxyl Terminus of the Vesicular Stomatitis Virus Glycoprotein G" Mol. and Cell. Biol. 4(2):282-289 (Feb. 1984).
Wilson, et al., "Mode of Inheritance of Decreased C3b Receptors on Erythrocytes of Patients with Systemic Lupus Erythematosis" N. Engl. J. Med. 307(16):981-986 (Oct. 1982).
Draper Garnette D.
Fitts Renee A.
Genentech Inc.
Lee Wendy M.
Spector Lorraine M.
LandOfFree
Methods and compositions for the attachment of proteins to lipos does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for the attachment of proteins to lipos, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for the attachment of proteins to lipos will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2385743